Background
R-CHOP had been the unimproved standard for DLBCL for two decades. POLARIX tested whether replacing vincristine with polatuzumab vedotin (anti-CD79b antibody-drug conjugate delivering MMAE) in the R-CHOP backbone (Pola-R-CHP) could improve outcomes in newly diagnosed intermediate-to-high-risk DLBCL.
Interventions and follow up
Arm A: Pola-R-CHP — polatuzumab vedotin 1.8 mg/kg + rituximab 375 mg/m2 + cyclophosphamide 750 mg/m2 + doxorubicin 50 mg/m2 + prednisone 100 mg days 1-5, every 21 days x6 cycles, then 2 cycles rituximab
Arm B: R-CHOP — rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone every 21 days x6 cycles, then 2 cycles rituximab
Population: N=879, untreated DLBCL, IPI ≥2
Primary endpoint: investigator-assessed PFS
Median follow-up: 28.2 months
Arm B: R-CHOP — rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone every 21 days x6 cycles, then 2 cycles rituximab
Population: N=879, untreated DLBCL, IPI ≥2
Primary endpoint: investigator-assessed PFS
Median follow-up: 28.2 months
Results
2-yr PFS: 76.7% vs 70.2% (HR 0.73, 95% CI 0.57–0.95, P=.02)
OS: 2-yr 88.7% vs 88.6% (HR 0.94, 95% CI 0.65–1.37, P=.75), NS
Complete response (PET-CT): 78.0% vs 74.0% (P=.16)
Subgroups: greatest PFS benefit in IPI 3–5 and non-GCB; no benefit in IPI 2
OS: 2-yr 88.7% vs 88.6% (HR 0.94, 95% CI 0.65–1.37, P=.75), NS
Complete response (PET-CT): 78.0% vs 74.0% (P=.16)
Subgroups: greatest PFS benefit in IPI 3–5 and non-GCB; no benefit in IPI 2
Adverse events
Overall: Grade 3-4 AEs 57.7% vs 57.5%; serious AEs 34.0% vs 30.6%
Hematologic: neutropenia (Grade 3-4) 41% vs 41%; febrile neutropenia 13.8% vs 8.0%
Neurologic: peripheral neuropathy any grade 52.9% vs 53.9% (comparable)
Other: no excess cardiac toxicity; treatment discontinuation comparable
Hematologic: neutropenia (Grade 3-4) 41% vs 41%; febrile neutropenia 13.8% vs 8.0%
Neurologic: peripheral neuropathy any grade 52.9% vs 53.9% (comparable)
Other: no excess cardiac toxicity; treatment discontinuation comparable
Conclusions
Pola-R-CHP significantly improved PFS over R-CHOP in IPI ≥2 DLBCL — the first regimen to improve upon R-CHOP in a phase III trial — with similar safety. No OS benefit was demonstrated at the primary analysis.
Key Limitations
No OS benefit; PFS gain (~6.5%) modest and absent in IPI 2 subgroup; benefit concentrated in higher-risk/non-GCB subsets identified post hoc; relatively short follow-up; cost and access to polatuzumab; double-hit/double-expressor and CNS-involved patients underrepresented.
Clinical Context
FDA approved Pola-R-CHP in April 2023 for previously untreated DLBCL/high-grade B-cell lymphoma with IPI ≥2; EMA approved 2022. ASCO/ESMO guidance positions Pola-R-CHP as a frontline option particularly for higher-IPI, non-GCB disease, while R-CHOP remains acceptable for lower-risk patients.